• Connect with us
    • Information
      • About Us
      • Contact Us
      • Careers
      • Partnerships
      • Advertise With Us
      • Authors
      • Browse Topics
      • Events
      • Disclaimer
      • Privacy Policy
    • Australia
      North America
      World
    Login
    Investing News NetworkYour trusted source for investing success
    • North America
      Australia
      World
    • My INN
    Videos
    Companies
    Press Releases
    Private Placements
    SUBSCRIBE
    • Reports & Guides
      • Market Outlook Reports
      • Investing Guides
    • Button
    Resource
    • Precious Metals
    • Battery Metals
    • Base Metals
    • Energy
    • Critical Minerals
    Tech
    Life Science
    Life Science Market
    Life Science News
    Life Science Stocks
    • Life Science Market
    • Life Science News
    • Life Science Stocks

    IMRIS Completes First Two Cases For Pediatric Horseshoe Headrest

    Investing News Network
    Mar. 26, 2014 08:16AM PST
    Life Science Investing

    IMRIS Inc. (TSX:IM,NASDAQ:IMRS) completed its first two cases using MR-safe headrest designed specifically for intraoperative imaging with VISIUS® intraoperative MRI (iMRI).

    IMRIS Inc. (TSX:IM,NASDAQ:IMRS) completed its first two cases using MR-safe headrest designed specifically for intraoperative imaging with VISIUS® intraoperative MRI (iMRI). The IMRIS horseshoe headrest is the world’s first MR-safe and CT-compatible horseshoe headrest on the market, used for neonatal to adult patients during neurosurgical procedures requiring intraoperative imaging in the VISIUS® Surgical Theatre.

    As quoted in the press release:

    “The IMRIS horseshoe headrest worked well for providing the ideal prone positioning during this procedure,” said Dr. Frederick Boop, Chairman of the Department of Neurosurgery and Co-director of Le Bonheur’s Neuroscience Institute who performed the first case of a tumor surgery on a five- year-old child. “In the past we would not have had an iMRI option for this child and now the tumor is completely gone. We have now advanced our treatment to a group of kids for whom it will really make a difference. Even our youngest and most fragile patients can benefit from intraoperative MR, which would not have been possible otherwise.”

    Click here to read the IMRIS Inc. (TSX:IM) press release

    The Conversation (0)

    Go Deeper

    AI Powered
    Ocumetics Technology

    Ocumetics Technology

    Intuitive Surgical

    Latest News

    Outlook Reports world

    Resource
    • Precious Metals
      • Gold
      • Silver
    • Battery Metals
      • Lithium
      • Cobalt
      • Graphite
    • Energy
      • Uranium
      • Oil and Gas
    • Base Metals
      • Copper
      • Nickel
      • Zinc
    • Critical Metals
      • Rare Earths
    • Industrial Metals
    • Agriculture
    Tech
      • Artificial Intelligence
      • Cybersecurity
      • Gaming
      • Cleantech
      • Emerging Tech
    Life Science
      • Biotech
      • Cannabis
      • Psychedelics
      • Pharmaceuticals

    Featured Stocks

    More featured stocks

    Browse Companies

    Resource
    • Precious Metals
    • Battery Metals
    • Energy
    • Base Metals
    • Critical Metals
    Tech
    Life Science
    MARKETS
    COMMODITIES
    CURRENCIES